March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Changes in Sphingolipid metabolism in the Vitreous from Diabetic Patients
Author Affiliations & Notes
  • Louis C. Glazer
    Vitreo-Retinal Associates, Grand Rapids, Michigan
    Ophthalmology,
    Michigan State University, East Lansing, Michigan
  • Todd A. Lydic
    Physiology,
    Michigan State University, East Lansing, Michigan
  • Kelly McSorley
    Physiology,
    Michigan State University, East Lansing, Michigan
  • Gavin E. Reid
    Chemistry,
    Michigan State University, East Lansing, Michigan
  • Susanne Mohr
    Physiology,
    Michigan State University, East Lansing, Michigan
  • Julia V. Busik
    Physiology,
    Michigan State University, East Lansing, Michigan
  • Footnotes
    Commercial Relationships  Louis C. Glazer, None; Todd A. Lydic, None; Kelly McSorley, None; Gavin E. Reid, None; Susanne Mohr, None; Julia V. Busik, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2215. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Louis C. Glazer, Todd A. Lydic, Kelly McSorley, Gavin E. Reid, Susanne Mohr, Julia V. Busik; Changes in Sphingolipid metabolism in the Vitreous from Diabetic Patients. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2215.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We have previously demonstrated in type 1 and type 2 diabetes animal models that upregulation of the central enzyme of sphingolipid metabolism, Acid Sphingomyelinase (ASM) plays an important role in the pathogenesis of diabetic retinopathy. ASM was upregulated in the retinas of donors with diabetic retinopathy compared to control. Moreover, we have shown a dramatic downregulation of long chain fatty acid elongases Elovl2 and Elovl4 in diabetic retina. Elovl4 has recently been shown to play a major role in production of very long chain fatty acids and in very long chain (≥C28) ceramide production in the skin. This study was designed to determine changes in the sphingolipid profile in the vitreous of diabetic patients.

Methods: : Vitrectomy samples were obtained from diabetic patients with active proliferative retinopathy (either vitreous hemorrhage or traction retinal detachment) or non-diabetic patients treated for macular hole. Vitreous sphingolipids were extracted with alkaline hydrolysis of gycerolipids, and sphingolipid profiles were determined by tandem mass spectrometry using precursor ion scanning of m/z 264 on a Thermo TSQ Vantage triple quadrupole mass spectrometer. Sphingolipid abundances were quantitated against appropriate internal standards.

Results: : Vitreous samples from the patients with diabetic retinopathy had increased ceramide, hexosylceramide and lactsylceramide levels. Interestingly, sphingomyelin levels were also increased in diabetic retinopathy vitreous samples. Detailed species analysis revealed that the increase in ceramide and sphingomyelin is mainly due to a dramatic upregulation of 24:0 species with concomitant down regulation of 26:0 and 28:0 species.

Conclusions: : Diabetes induced changes in retinal sphingomyelinases and fatty acid elongases leads to dramatic upregulation of sphingolipids in the vitreous mainly due to accumulation of 24:0 species. Overall, our study indicates that changes in sphingolipid metabolism play a role in the development of diabetic retinopathy.

Keywords: diabetic retinopathy • lipids • pathology: human 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×